Items Tagged ‘News’

May 1, 2019

ASCO Guideline: Oxaliplatin Adjuvant Therapy for Stage III Colon Cancer May Be Reduced in Select Patients

By

The American Society of Clinical Oncology (ASCO) has released a new guideline that states that patients with clinically low-risk stage III colon cancer should have the option of receiving 3 months of adjuvant oxaliplatin-based chemotherapy. For patients at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration of […]

View full entry

Tags: Colon Cancer, News


April 30, 2019

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer

By

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer (ESBC).(1) In the United States “dose dense” chemotherapy is considered standard of care for the treatment […]

View full entry

Tags: Breast Cancer, News


April 16, 2019

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

By

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Today, […]

View full entry

Tags: Bladder Cancer, News


April 11, 2019

Most women can get mammograms every other year starting at age 50

By

Women who are not at high risk for breast cancer can wait to start getting mammograms until age 50 and be screened every other year, according to new guidelines from the American College of Physicians. Women at high risk for breast cancer are those with a family history of breast cancer, previous cancer scares, dense […]

View full entry

Tags: News


April 8, 2019

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer

By

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in the Early Breast Cancer Trialists Collaborative Group who evaluated 37,000 women who participated in 26 clinical trials […]

View full entry

Tags: Breast Cancer, News


April 4, 2019

CD40 Combination Therapy Can Shrink Pancreatic Tumors

By

A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients – 20 out of 24 as of an interim analysis of the phase 1b trial data. The early findings provide hope that this strategy involving a CD40 antibody, a checkpoint inhibitor, and standard-of-care chemotherapy could […]

View full entry

Tags: News, Pancreatic Cancer


March 28, 2019

GARNET Study Suggets Dostarlimab Promising for Uterine/Endometrial Cancer

By

An early phase clinical trial evaluating dostarlimab in women with recurrent or advanced endometrial cancer appears promising.  These data were presented at the 2019 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Honolulu, Hawaii. Endometrial cancer (EC) is the most common gynaecologic malignancy in the U.S. but there are limited treatment options […]

View full entry

Tags: News, Uterine Cancer


March 26, 2019

NCCN Updates Ovarian Cancer Guidelines

By

The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes. All patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer should have a genetic risk evaluation and BRCA1/2 testing performed. Maintenance Therapy: Lynparza (olaparib) was added as a maintenance therapy option after complete or partial clinical remission […]

View full entry

Tags: News, Ovarian Cancer


March 20, 2019

Prophylactic Cranial Irradiation Improves Disease-Free Survival and Brain Metastasis Rates for Locally Advanced Non-Small Cell Lung Cancer

By

PHILADELPHIA, PA– Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer […]

View full entry

Tags: Lung Cancer - Non-Small Cell, News


March 18, 2019

Lynparza Delays Progression of BRCA-mutated Metastatic Pancreatic Cancer

By

Lynparza (olaparib) improves progression-free survival (PFS) when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer. (1-4) About BRCA Mutated Pancreatic Cancer Pancreatic cancer has the worst survival rate of the most common cancers and less than seven percent of patients survive more than […]

View full entry

Tags: News, Pancreatic Cancer


March 14, 2019

Darolutamide Delays Prostate Cancer Progression in Men with Resistant Prostate Cancer

By

Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer Darolutamide treated patients survived an average of 40.4 months with evidence of metastases compared to […]

View full entry

Tags: News, Prostate Cancer


March 11, 2019

Non-Chemotherapy Combo Approved for Treatment-Naïve CLL/SLL Patients

By

The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) in combination with Gazyva (obinutuzumab) for treatments of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). 1 The FDA approval was based on results from the Phase 3 iLLUMINATE clinical trial which compared Gazyva administered with either Imbruvica or chlorambucil in 212 adult patients. […]

View full entry

Tags: Leukemia, News


March 8, 2019

FDA Approves Lonsurf® for Treatment of Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

By

The United States Food and Drug Administration (FDA) has approved Lonsurf® (trifluridine/tipiracil)) as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. About Lonsurf Lonsurf consists of […]

View full entry

Tags: Gastric Cancer, News


March 4, 2019

FDA Approves Keytruda for Adjuvant Treatment of Melanoma

By

On February 15, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Approval was based on EORTC1325/KEYNOTE‑054 (NCT02362594), a randomized, double-blind, placebo-controlled, trial in 1019 patients with completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC […]

View full entry

Tags: Melanoma, News


February 28, 2019

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer

By

Results from the trial showed a significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) for the treatment of BRCA-mutated pancreatic cancer. POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose […]

View full entry

Tags: News, Pancreatic Cancer